anti-F11R antibody product blog
Tags: Antibody; Polyclonal Antibody; F11R; anti-F11R antibody; JAM-A, Domain 2;
The F11R f11r (Catalog #MBS644275) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The JAM-A, Domain 2 (Junctional Adhesion Molecule A, Junctional Adhesion Molecule 1, JAM-1, Platelet F11 Receptor, Platelet Adhesion Molecule 1, PAM-1, CD321, F11R, JAM1, JCAM, UNQ264/PRO301) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s JAM-A, Domain 2 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB), Immunohistochemistry (IHC), Flow Cytometry (FC/FACS).Suitable for use in Flow Cytometry, ELISA, Western Blot and Immunohistochemistry.
Dilution: Immunohistochemistry: Paraffin
Flow Cytometry: 1:50
Western Blot: 1:50. Researchers should empirically determine the suitability of the F11R f11r for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The F11R f11r product has the following accession number(s) (GI #8393638) (NCBI Accession #NP_058642.1) (Uniprot Accession #Q9Y624). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Junction adhesion molecule (JAM)-A (also known as JAM, JAM-1 or F11R). Together with JAM-C (JAM-2) and JAM-B (VE- JAM or JAM-3), JAM-A belongs to a family of adhesion proteins with a V-C2 immunoglobulin domain organization. JAMs are important for a variety of cellular processes, including tight junction assembly, leukocyte transmigration, platelet activation, angiogenesis and virus binding. JAM-An is expressed by endothelial and epithelial cells, platelets, neutrophils, monocytes, lymphocytes and erythrocytes. Like all other JAMs, JAM-A play an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interaction. It codistributes with other tight junction components as ZO-1, 7H6 antigen, cingulin and occludin. JAM-An also plays an important role in leukocyte transmigration. Leukocyte transmigration can be blocked by antibodies and by soluble JAM-A/Fc fusion proteins. Homophilic JAM-An interactions between leukocytes and the endothelium but also heterophilic interactions of JAM-A with the b2-integrin leukocyte function-associated antigen-1 (LFA-1) are considered to actively guide leukocytes during transmigration. Several studies imply a role of JAM-An in the initiation of atherosclerosis, since JAM-An is upregulated on early atherosclerotic endothelium and adhesion of activated platelets on activated endothelium is mediated by homophilic interactions of JAM- A. The polyclonal antibody reacts with the 17kD extracellular domain 2 of the human JAM-A protein.
Immunogen: Extracellular domain from full-length human JAM-A. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing F11R are readily searchable from our website. Different antibodies against the same target such as F11R may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.